PR85094

SEATTLE, Aug. 13, 2020 /PRNewswire=KYODO JBN/ --

AGC Biologics, a global biopharmaceutical Contract Development and

Manufacturing Organization (CDMO), announced it is partnering with Ono

Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative biopharmaceuticals

at the clinical development stage. ONO is a R&D-oriented pharmaceutical company

committed to discovering and developing innovative drugs.

Logo - https://mma.prnewswire.com/media/624983/AGC_Biologics_logo_Logo.jpg 

"We are very pleased to initiate this partnership with ONO," said Mark Womack,

CBO of AGC Biologics. "We look forward to closely collaborating with ONO to

manufacture innovative and important therapies."

AGC Biologics' global network spans three continents, with cGMP-compliant

facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark;

Heidelberg, Germany; Milan and Bresso, Italy and Chiba, Japan. Their best in

class services include development and manufacturing of mammalian and

microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and

genetically engineered cells.

About ONO:  

ONO, headquartered in Osaka, is committed to creating innovative medicines in

specific areas. ONO focuses its research on the oncology, immunology, neurology

and specialty research with high medical needs as priority areas for discovery

and development of innovative medicines. For further information, please visit

the company's website at www.ono.co.jp/eng .

About AGC Biologics:  

AGC Biologics is a leading global Biopharmaceutical Contract Development and

Manufacturing Organization (CDMO) with a strong commitment to deliver the

highest standard of service to clients and partners. The company currently

employs more than 1,300 employees worldwide.  AGC Biologics has decades of

experience in CDMO development and manufacturing, including providing

commercial market supply with FDA, PDMA and EMA approvals.

AGC Biologics offers deep industry expertise and unique customized services.

Integrated service offerings include cell line development, bioprocess

development, formulation, analytical testing, antibody drug development and

conjugation, cell banking and storage and protein expression, including the

proprietary CHEF1(R) Expression System for mammalian production.

AGC Biologics is committed to continuous innovation and offers the technical

creativity to solve clients' most complex challenges, including specialization

in fast-track projects for orphan drugs and rare diseases.

Learn more at www.agcbio.com.

SOURCE: AGC Biologics

CONTACT: Diane Hunt, dhunt@agcbio.com, http://www.agcbio.com/